ziv-aflibercept (Rx)

Brand and Other Names:Zaltrap
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 25mg/mL (4-mL, 8-mL single-dose vials)

Colorectal Cancer

Indicated in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) for metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin regimen

4 mg/kg IV q2weeks; administer before any component of the FOLFIRI regimen on the day of treatment  

Continue until disease progression or unacceptable toxicity occurs

Dosage Modifications

Discontinue

  • Severe hemorrhage
  • Gastrointestinal perforation
  • Impaired wound healing
  • Fistula formation
  • Hypertensive crisis or hypertensive encephalopathy
  • Arterial thromboembolic events
  • Nephrotic syndrome or thrombotic microangiopathy (TMA)
  • Reversible posterior leukoencephalopathy syndrome (RPLS)

Temporarily suspend

  • At least 4 weeks prior to elective surgery
  • For recurrent or severe hypertension, until controlled; once resumed, permanently reduce dose to 2 mg/kg
  • Proteinuria >2 g/24 hr; resume when proteinuria <2 g/24 hr
  • For recurrent proteinuria, suspend therapy until proteinuria <2 g/24 hr and then permanently reduce dose to 2 mg/kg

Renal impairment

  • No dosage adjustment necessary

Hepatic impairment

  • Mild-to-moderate (total bilirubin >1 to ≤3x ULN and any AST): No dosage adjustment necessary
  • Severe (total bilirubin >3x ULN): Not studied

Safety and efficacy not established

Next:

Adverse Effects

>10%

All grades

  • Leukopenia (78%)
  • Diarrhea (69%)
  • Neutropenia (67%)
  • Proteinuria (62%)
  • AST increased (62%)
  • ALT increased (50%)
  • Stomatitis (50%)
  • Thrombocytopenia (48%)
  • Fatigue (48%)
  • Hypertension (41%)
  • Decreased weight (32%)
  • Decreased appetite (32%)
  • Epistaxis (28%)
  • Abdominal pain (27%)
  • Dysphonia (25%)
  • Increased serum creatinine (23%)
  • Asthenia (18%)
  • Dyspnea (12%)
  • Upper abdominal pain (11%)

Grade 3-4

  • Neutropenia (37%)
  • Diarrhea (19%)
  • Hypertension (19%)
  • Leukopenia (16%)
  • Stomatitis (13%)
  • Fatigue (13%)
  • Palmar-plantar erythrodysesthesia syndrome (11%)

1-10%

All grades

  • Urinary tract infection (9%)
  • Oropharyngeal pain (8%)
  • Skin hyperpigmentation (8%)
  • Venous thromboembolic events (9%)
  • Hemorrhoids (6%)
  • Rectal hemorrhage (5%)
  • Proctalgia (5%)
  • Pulmonary embolism (5%)

Grade 3-4

  • Proteinuria (8%)
  • Asthenia (5%)
  • Abdominal pain (4%)
  • Palmar-plantar erythrodysesthesia syndrome (3%)
  • Thrombocytopenia (3%)
  • AST increased (3%)
  • ALT increased (3%)
  • Decreased weight (3%)
  • Decreased appetite (3%)
  • Upper abdominal pain (1%)

<1%

Grade 3-4

  • Dyspnea (0.8%)
  • Rectal hemorrhage (0.7%)
  • Dysphonia (0.5%)
  • Proctalgia (0.3%)
  • Epistaxis (0.2%)
  • Oropharyngeal pain (0.2%)

Posmarketing Reports

Arterial (including aortic), aneurysms, dissections, and rupture

Previous
Next:

Warnings

Contraindications

None

Cautions

Increased risk of hemorrhage, including severe and sometimes fatal hemorrhagic events (eg, severe intracranial hemorrhage, pulmonary hemorrhage/hemoptysis); monitor for signs and symptoms of bleeding, and discontinue if needed; do not administer with severe hemorrhage

Gastrointestinal (GI) perforation including fatal GI perforation can occur; monitor for signs and symptoms of bleeding, and discontinue if needed

Grade 3 impaired wound healing was reported; suspend therapy for ≥4 weeks prior to elective surgery; resume therapy ≥4 weeks following major surgery or until surgical wound has healed; for minor surgical procedures (eg, tooth extraction, biopsy, central venous access port placement), resume therapy once surgical wound has healed completely; discontinue in patients with compromised wound healing

Increased risk of fistula formation involving GI and non-GI sites; discontinue if fistula develops

Increased risk of Grade 3-4 hypertension; monitor BP q2weeks or more frequently if indicated; treat with appropriate antihypertensive therapy; temporarily suspend if hypertension uncontrolled, and permanently reduce dose to 2 mg/kg for subsequent cycles once blood pressure normalizes; discontinue with hypertensive encephalopathy or hypertensive crisis

Increased risk of arterial thromboembolic events (eg, TIA, CVA, and angina pectoris); discontinue if thromboembolic event occurs

Increased risk of higher incidence of neutropenic complications (febrile neutropenia and neutropenic infection); monitor CBC with differential count at baseline and prior to initiation of each cycle; delay if neutrophil count ≥1.5 x 109/L

Increased risk of severe diarrhea, especially in patients aged ≥65 years; monitor closely

Increased risk of RPLS (also known as posterior reversible leukoencephalopathy syndrome); confirm RPLS diagnosis with MRI and discontinue if present; RPLS may resolve or improve within days, but some patients have experienced ongoing neurologic sequelae or death

May cause fetal harm based on findings from animal studies and its mechanism of action

Proteinuria

  • Severe proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) occurred more frequently
  • Monitor by urine dipstick analysis and urinary protein creatinine ratio (UPCR)
  • Obtain 24-hour urine collection in patients with UPCR ≥1; suspend if proteinuria is ≥2 g/24hr, and resume when ≤2 g/24hr; if reoccurs, suspend until ≤2 g/24hr and permanently reduce dose to 2 mg/kg for subsequent cycles; discontinue in patients who develop TMA or nephrotic syndrome
Previous
Next:

Pregnancy & Lactation

Pregnancy

Based on findings from animal reproduction studies and its mechanism of action, fetal harm may cause when administered to pregnant women

Insufficient data available in pregnant women exposed to ziv-aflibercept to assess the risk

Advise pregnant women of the potential risk to a fetus

Animal data

  • Administration of ziv-aflibercept during organogenesis was embryotoxic and teratogenic in rabbits at exposure levels ~0.3 times the human exposure at the 4 mg/kg/dose

Pregnancy testing

  • Verify pregnancy status in females of reproductive potential before initiating ziv-aflibercept

Contraception

  • Females or reproductive potential: Use effective contraception during treatment and for 1 month following the last dose

Infertility

  • Advise female and male patients of reproductive potential that treatment may impair reproductive function and fertility

Lactation

There are no data on presence of drug in human milk, or effects on breastfed infant or on milk production

Owing to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 month following last dose

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Recombinant fusion protein; soluble receptor that binds to human VEGF-A, VEGF-B and P1GF; binding to these endogenous ligands leads to inhibition of binding and activation of their cognate receptors, which can result in decreased neovascularization and decreased vascular permeability; in animals, shown to inhibit proliferation of endothelial cells, leading to inhibition of growth of new blood vessels

Absorption

Steady state concentrations reached by second dose

Patients weighing ≥100 kg had a 29% increase in systemic exposure compared to patients weighing 50-100 kg

Distribution

Accumulation ratio: 1.2 (4mg/kg q2Week)

Elimination

Half-life: 6 days (4mg/kg q2Week)

Previous
Next:

Administration

IV Compatibilities

0.9% NaCl

Dextrose 5% (D5W)

IV Preparation

Clear, colorless to pale yellow solution; do not use if solution if discolored or cloudy

Do not re-enter vial after initial puncture; discard unused portion

Withdraw prescribed dose and dilute in 0.9% NaCl or D5W to achieve final concentration of 0.6–8 mg/mL; use PVC infusion bags containing DEHP or polyolefin infusion bags

IV Administration

Administer diluted solution as IV infusion over 1 hr through a 0.2 micron polyethersulfone filter

Do not use filters made of polyvinylidene fluoride (PVDF) or nylon

Do not combine with other drugs in same infusion bag or IV line

Infusion set compatibility: Administer using infusion set of PVC containing DEHP, DEHP free PVC containing TOTM, polypropylene, polyethylene lined PVC, or polyurethane

Do not administer as an IV bolus

Storage

Unopened vials: Refrigerator at 2-8°C (36-46°F); keep in the original outer carton to protect from light

Diluted bags: May refrigerate at 2-8°C (36-46°F) for up to 4 hr; discard unused portion

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Zaltrap intravenous
-
200 mg/8 mL (25 mg/mL) vial
Zaltrap intravenous
-
100 mg/4 mL (25 mg/mL) vial

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

Patient Education
ziv-aflibercept intravenous

ZIV-AFLIBERCEPT - INJECTION

(a-FLIB-er-sept)

COMMON BRAND NAME(S): Zaltrap

USES: Ziv-aflibercept is used to treat cancer of the colon and rectum.

HOW TO USE: This medication is given by injection into a vein by a health care professional. It is given as directed by your doctor, usually every 2 weeks. The medication is injected slowly into a vein over 1 hour.The dosage is based on your medical condition, weight, and response to treatment.You should receive this medication regularly to get the most benefit from it. To help you remember, mark your calendar to keep track of when to receive the next dose.

SIDE EFFECTS: Diarrhea, headache, mouth pain/sores, runny nose, voice changes, weight loss, weakness, tiredness, or darkening of the skin may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: signs of kidney problems (such as change in the amount of urine), swelling hands/ankles/feet, severe/persistent diarrhea, signs of dehydration (such as muscle cramps, extreme thirst, dizziness), pain/redness/swelling/tingling/burning of the hands/feet, slow wound healing.Get medical help right away if you have any very serious side effects, including: chest/jaw/left arm pain, weakness on one side of the body, trouble speaking, confusion, sudden vision changes, seizure, sudden/severe back pain or headache.This medication may cause serious (possibly fatal) bleeding. It may also rarely cause a hole to open in the stomach or intestines (gastrointestinal perforation). Tell your doctor right away if you have symptoms such as stomach/abdominal pain that doesn't go away, easy or unusual bleeding/bruising (such as from cuts, gums, nosebleeds), pink/dark urine, bloody or black/tarry stools, vomit that looks like coffee grounds, coughing up blood, lightheadedness, unusual tiredness/weakness.This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor right away if you have any signs of infection (such as sore throat that doesn't go away, fever, chills, cough).This medication may raise your blood pressure. Check your blood pressure regularly and tell your doctor if the results are high. Your doctor may control your blood pressure with medication.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Before receiving ziv-aflibercept, tell your doctor or pharmacist if you are allergic to it; or to aflibercept; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: high blood pressure, kidney disease, recent surgery, recent injuries/wounds, recent/current infection, blood/bone marrow disorders (such as low platelet/neutrophil/red blood cell levels), bleeding problems (such as bleeding of the stomach/intestines), blood vessel problems (such as an aneurysm or a tear/break in the aorta or other blood vessels).Before having surgery or any medical procedure, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).This medication may cause wounds to heal slowly or poorly. You should not receive this medication for at least 4 weeks before and at least 4 weeks after major surgery, until wounds from the surgery are fully healed. Ask your doctor for specific instructions about when to stop and when to restart treatment with this medication.Ziv-aflibercept can make you more likely to get infections or may worsen any current infections. Avoid contact with people who have infections that may spread to others (such as chickenpox, measles, flu). Consult your doctor if you have been exposed to an infection or for more details.Do not have immunizations/vaccinations without the consent of your doctor. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose).To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.Older adults may be more sensitive to the side effects of this drug, especially diarrhea, dehydration, weight loss, and weakness.Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using ziv-aflibercept. Ziv-aflibercept may harm an unborn baby. Your doctor should order a pregnancy test before you start this medication. Ask about reliable forms of birth control while using this medication and for 1 month after stopping treatment. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breast-feeding is not recommended while using this drug and for 1 month after stopping treatment. Consult your doctor before breast-feeding.

DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Ziv-aflibercept is very similar to aflibercept. Do not use ziv-aflibercept while using the form of aflibercept that is also given by injection into a vein.

OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Lab and/or medical tests (such as blood pressure, urine protein, complete blood count, liver function) should be done while you are using this medication. Keep all medical and lab appointments.

MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.

STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).

Information last revised September 2021. Copyright(c) 2021 First Databank, Inc.

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.